clinical trials
EMA selects TrialAssure anonymisation platform for clinical trial documents
July 30, 2026EMA, TrialAssure, clinical trials
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency (EMA) for use as an …
Richmond Pharmacology appoints Dr Edward Jackson as Medical Director
November 7, 2025CRO, Richmond Pharmacology, biotech, clinical trials
Richmond Pharmacology, a contract research organisation (CRO) specialising in first-in-human and adaptive clinical trials, has appointed Dr Edward Jackson as …
Vesper Bio reports positive topline results for dementia candidate
November 7, 2025Research and Development Frontotemporal degeneration, Vesper Bio, clinical trials, dementia
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has reported positive topline data from …
Von Willebrand disease – increasing awareness and access to vital care
November 4, 2025Medical Communications, Research and Development European Medicines Association, Haematology, Takeda, Von Willebrand Disease, clinical trials, disease awareness
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about Von Willebrand disease, its causes …
Rethinking oncology trial endpoints with generalised pairwise comparisons
November 4, 2025Research and Development EMA, FDA, Oncology, One2Treat, clinical trials, generalised pairwise comparisons, net treatment benefit, oncology
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival (OS) and progression-free survival (PFS) …
Evestia Clinical and Atlantic Research Group merge to create global specialist CRO
July 23, 2025Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation
UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
July 8, 2025Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
July 1, 2025Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
June 27, 2025Research and Development Dermatology, Galderma, chronic pruritus of unknown origin, clinical trials, dermatological conditions, dermatology, nemolizumab, systemic sclerosis
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic …
CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
June 26, 2025Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Roche advances treatment for Parkinson’s disease
June 16, 2025Research and Development Neurology, Parkinson's disease, Roche, clinical trials, neurodegenerative disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s …
Meteor Biotech opens site at UCLA to support biotech research
June 11, 2025Biotech/start-up, Research and Development, Sales and Marketing Devices, Immunology, Meteor Biotech, Oncology, Pharmacy, University of California Los Angeles, cell sorting technology, clinical trials, research facility
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international office at the California NanoSystems …
Newron’s programme for treatment-resistant schizophrenia therapy approved
May 13, 2025Research and Development Newron, Psychiatry, clinical trials, psychiatry, schizophrenia
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study
February 14, 2025Clinical Research Opthalmology, age-related macular degeneration, clinical trials
Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be …
